PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW127474View Pathway |
drug action
Tenofovir Disoproxil Action PathwayHomo sapiens
Tenofovir disoproxil is a prodrug, nucleotide analog reverse transcriptase inhibitor used to treat Hepatitis B infection and used to manage HIV-1 infection. This drug prevents viral DNA chain elongation through inhibition of enzymes necessary for host cell infection viral replication in HIV-1 and Hepatitis B infections. Tenofovir disoproxil fumarate is the fumarate salt of the prodrug tenofovir disoproxil. Tenofovir disoproxil is absorbed and converted to its active form, tenofovir, a nucleoside monophosphate (nucleotide) analog. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, a chain terminator, by constitutively expressed enzymes in the cell.
Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the Hepatitis B polymerase by direct binding in competition with dATP. After integration into DNA, causes viral DNA chain termination. Tenofovir diphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once tenofovir diphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed.
|
Creator: Ray Kruger Created On: March 08, 2023 at 14:17 Last Updated: March 08, 2023 at 14:17 |
PW144428View Pathway |
drug action
Tenofovir disoproxil Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:37 Last Updated: October 07, 2023 at 13:37 |
PW000606View Pathway |
Tenofovir Metabolism PathwayHomo sapiens
Tenofovir is a nucleotide analogue used in the treatment of HIV and chronic hepatitis B. It is taken up into the cell and is subsequently phosphorylated first by adenylate kinases and then by nucleoside diphosphate kinases into tenofovir diphosphate. Tenofovir diphosphate is an analogue of deoxyadenosine triphosphate (dATP) and competes with dATP for binding to the viral DNA polymerase and subsequent incorporation into the growing DNA strand. Once incorporated into the DNA, tenofovir causes chain termination, thus preventing viral replication.
|
Creator: WishartLab Created On: September 11, 2013 at 22:33 Last Updated: September 11, 2013 at 22:33 |
PW000683View Pathway |
drug action
Tenoxicam Action PathwayHomo sapiens
Tenoxicam (also named mobiflex and tilcotil) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to reduce inflammation, swelling, stiffness, and pain that are associated with various diseases such as tendinitis, bursitis and etc. Tenoxicam can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of tenoxicam.
|
Creator: WishartLab Created On: April 26, 2014 at 13:14 Last Updated: April 26, 2014 at 13:14 |
PW126072View Pathway |
drug action
Tenoxicam Action Pathway (New)Homo sapiens
Tenoxicam is an anti-inflammatory analgesic used to treat mild to moderate pain as well as the signs and symptoms of rheumatoid arthritis and osteoarthritis. It also has antipyretic effects. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 converts arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. Tenoxicam inhibits the action of COX-1 and COX-2 on the endoplasmic reticulum membrane. This reduces the formation of prostaglandin H2 and therefore, prostaglandin E2 (PGE2). The low concentration of prostaglandin E2 attenuates the effect it has on stimulating immune cells and pain fibers, consequently reducing inflammation and pain. Fever is triggered by inflammatory and infectious diseases. Cytokines are produced in the central nervous system (CNS) during an inflammatory response. These cytokines induce COX-2 production that increases the synthesis of prostaglandin, specifically prostaglandin E2 which adjusts hypothalamic temperature control by increasing heat production. Because tenoxicam decreases PGE2 in the CNS, it has an antipyretic effect. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
|
Creator: Karxena Harford Created On: June 09, 2021 at 00:36 Last Updated: June 09, 2021 at 00:36 |
PW144591View Pathway |
drug action
Tenoxicam Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:58 Last Updated: October 07, 2023 at 13:58 |
PW146908View Pathway |
drug action
Tepotinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:20 Last Updated: October 07, 2023 at 19:20 |
PW145250View Pathway |
drug action
Terazosin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:24 Last Updated: October 07, 2023 at 15:24 |
PW176408View Pathway |
Terazosin Predicted Metabolism PathwayHomo sapiens
Metabolites of Terazosin are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 16:56 Last Updated: December 07, 2023 at 16:56 |
PW126656View Pathway |
drug action
Terbinafine Action PathwayHomo sapiens
Terbinafine (commonly known as Lamisil or Silka cream) is a synthetic allylamine anti-fungal used mainly for athletes foot and other fungal skin infections. While Terbinafine is most commonly used against the fungus species Trichophyton rubrum and Trichophyton mentagrophytes, but the ergosterol biosynthesis pathway for these species has not been studies enough to know the enzymes used for sure. Candida albicans is a fungus that Terbinafine can be used against and the enzyme squalene monooxygenase, which is the enzyme inhibited by this drug, has been properly researched for Candida albicans where it hasn't for other fungus species. Terbinafine can also be used against other Trichophyton species; Microsporum canis; Epidermophyton floccosum,11; Tinea species; Candida albicans and Malassezia furfur if infections of the skin.
Terbinafine works by inhibiting squalene monooxygenase which is an essential enzyme of Ergosterol biosynthesis. Terbinafine is transported into the fungal cell vis diffusion. Squalene monooxygenase catalyzes the synthesis of (S)-2,3-epoxysqualene from squalene. Since it is inhibited, it cannot continue on to synthesize lanosterol which is essential in the synthesis of ergosterol. Without ergosterol in the cell membrane, the cell membrane sees increased permeability which allows intracellular components to leak out of the cell. Ergosterol is also essential in cell membrane integrity so without that, eventually the cell collapses and dies.. The fungal cell also cannot synthesize new cell membranes for new fungus cells if there is no ergosterol. The inhibition of squalene monooxygenase also causes a buildup of squalene which is toxic to the fungal cell.
|
Creator: Ray Kruger Created On: February 09, 2022 at 16:20 Last Updated: February 09, 2022 at 16:20 |